Literature DB >> 8449608

Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability.

S Folli1, A Pèlegrin, Y Chalandon, X Yao, F Buchegger, D Lienard, F Lejeune, J P Mach.   

Abstract

Marked differences in the tumor uptake of a 125I-labeled monoclonal antibody (MAb) directed against carcinoembryonic antigen (CEA) were observed in 4 serially transplanted human colorectal carcinomas in nude mice. A comparative study showed that elevated values of measurable tumor vascular parameters, such as permeability, blood flow and blood volume, correlated better with high MAb tumor uptake than the concentration of target antigen in the tumor. In an attempt to modify the vascular parameters and to determine if this could increase antibody uptake by the tumor, rhTNF alpha (TNF) was injected i.t. or i.v. and antibody localization experiments were performed immediately thereafter. Results showed that the permeability of the tumor vessels increased 8 to 10 fold 1 hr after i.t. injection of TNF as compared to control tumors injected with saline. Tumor uptake of 125I-labeled anti-CEA MAb, was 3 times higher 2 hr after i.v. injection and still 27% higher 22 hr later, as compared to results from controls. Intravenous injection of TNF simultaneously with the 125I-labeled anti-CEA MAb also resulted in a 2-fold increase in tumor uptake 4 hr after injection, but the increase was no longer significant 24 hr after injection. Interestingly after i.v. injection of TNF, the MAb concentration in the blood and other normal tissues, such as liver, kidneys, lungs and heart was decreased, resulting in significantly higher ratios of tumor to normal tissue. Taken together the results demonstrate that injection of TNF can increase tumor vascular permeability and improve radio-antibody uptake. This raises the possibility of increasing the radiation dose delivered by antibody to the tumor in the course of radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449608     DOI: 10.1002/ijc.2910530521

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.

Authors:  Shutao Wang; In Soo Shin; Hilary Hancock; Beom-su Jang; Hyung-sub Kim; Sang Myung Lee; Vesna Zderic; Victor Frenkel; Ira Pastan; Chang H Paik; Matthew R Dreher
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

3.  T cell activation alters intestinal structure and function.

Authors:  Michael Field
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

Review 4.  Introduction to monoclonal antibodies.

Authors:  Jean-Pierre Mach
Journal:  Cancer Immun       Date:  2012-05-01

5.  Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.

Authors:  Chandrakala Menon; Antoinette Ghartey; Robert Canter; Michael Feldman; Douglas L Fraker
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

6.  Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.

Authors:  G Spitaleri; R Berardi; C Pierantoni; T De Pas; C Noberasco; C Libbra; R González-Iglesias; L Giovannoni; A Tasciotti; D Neri; H D Menssen; F de Braud
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-17       Impact factor: 4.553

Review 7.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

Review 8.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

Review 9.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.